TB-500
A fragment of a protein your body already makes. Human trials exist, which is unusual here, but they were for eyes and wounds rather than joints.
Not approved anywhere
| What it is | TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring protein involved in cell migration and wound repair. |
|---|---|
| How it is thought to work | Thymosin beta-4 binds actin and helps cells move to a wound site. It also promotes blood vessel formation and reduces inflammatory signalling. |
| What the evidence actually shows | Full-length thymosin beta-4 reached human trials for dry eye disease and non-healing wounds. Results were mixed and it was not approved. Joint and tendon claims rest on animal work, not those trials. |
| Regulatory status | Not approved in the US in any form. Sold as a research chemical. |
| Dosing | No established human dose for musculoskeletal use. The eye and wound trials used topical or local formulations, not systemic injection, so their doses do not transfer. |
| In the catalog as |
Risks and cautions
- Same angiogenesis question as BPC-157: unstudied long-term in humans.
- Prohibited in sport by WADA.
Before you act on any of this
This page describes what is known and what is not. It is not a recommendation to use anything, and it is not a protocol. Compounds listed as research chemicals are not approved medicines and are not sold for human use. Talk to a doctor who knows your history.